Radiopharmaceutical firm Coulter Pharmaceuticals reported losses for both the fourth quarter and fiscal year 1999 (end-December). The company posted quarter losses of $14.5 million, compared to net income of $25.5 million in 1998, and dramatic year-end
Radiopharmaceutical firm Coulter Pharmaceuticals reported losses for both the fourth quarter and fiscal year 1999 (end-December). The company posted quarter losses of $14.5 million, compared to net income of $25.5 million in 1998, and dramatic year-end losses of $50.6 million, compared to $2 million the year before. The South San Francisco, CA, company attributed these results to increased operating expenses to support its R&D and commercialization activities for Bexxar, the cancer therapy product Coulter is developing with SmithKline Beecham for the treatment of non-Hodgkins lymphoma. Coulter ended the year with cash assets of $82 million.
In other Coulter news, the firm has received a composition patent from the U.S. Patent and Trademark Office. Arising from Coulters work on Bexxar, the patent covers radiolabeled monoclonal antibodies for the treatment of B-cell lymphomas, and strengthens Coulters position in the field of radioimmunotherapy, according to president and CEO Michael Bigham.
European Society of Breast Imaging Issues Updated Breast Cancer Screening Recommendations
April 24th 2024One of the recommendations from the European Society of Breast Imaging (EUSOBI) is annual breast MRI exams starting at 25 years of age for women deemed to be at high risk for breast cancer.
Study Reveals Benefits of Photon-Counting CT for Assessing Acute Pulmonary Embolism
April 23rd 2024In comparison to energy-integrating detector CT for the workup of suspected acute pulmonary embolism, the use of photon-counting detector CT reduced radiation dosing by 48 percent, according to newly published research.
Could a Newly FDA-Cleared C-Arm Device Bolster Efficiency for Interventional Radiologists?
April 22nd 2024In addition to advanced imaging quality and dose efficiency, the Philips Zenition 30 mobile C-arm device emphasizes personalized user profiles and automated customization to help reduce procedure time.